Moxonidine

This classification denotes an antihypertensive agent with the molecular formula C9H12ClN5O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier CC6X0L40GW, chemically known as 5-pyrimidinamine, 4-chloro-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methoxy-2-methyl- (9ci) but generally known as moxonidine, which bears US NIH Compound Identifier 4810. European Medicines Agency schedules Moxonidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09092MIG. The term MOXONIDINE is an International Non-Proprietary Name. World Health Organization schedules moxonidine in its Anatomical Therapeutic Chemical (ATC) Classification. MOXONIDINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule moxonidine under HS 29335995 and SITC 51576. As of Q4 2014, MOXONIDINE remains the US FDA Preferred Term for this commodity. Moxonidine bears US NLM identifiers UMLS ID C0066837 and NCI Concept Code C87629. SMILES: Clc1nc(nc(OC)c1NC1=NCCN1)C.